Diabetic Foot Ulcer Treatment Market Outlook, Trends And Future Opportunities (2024-2031)

Diabetic Foot Ulcer Treatment Market is Forecasted to Hit US$ 7.4 Bn By 2031 | CAGR 5.5%

  • Date: 28 Mar, 2024
  • Author(s): Sagar Karlekar

Global Diabetic Foot Ulcer Treatment Market is expected to reach US$ 7.4 Bn in 2031 with a growth rate of 5.5%. The diabetic foot ulcer treatment market consists of medical devices, wound care products, and drugs used to treat foot ulcers in diabetic patients. Growth in this market is being driven by the increasing prevalence of diabetes and diabetes-related complications such as diabetic foot ulcers globally.

Diabetic foot ulcers are a major complication of diabetes mellitus and often lead to infection, gangrene, and amputation if not treated properly. With the growing diabetes population, especially in developing regions, the demand for advanced diabetic foot ulcer treatment options is increasing. Key factors propelling market growth include rising awareness about diabetes care, introduction of novel wound care products, and increasing investments in R&D to develop advanced therapeutic drugs and devices.

The growing adoption of novel therapies such as growth factors, skin substitutes, negative pressure wound therapy devices, and hyperbaric oxygen therapy is boosting the market growth. Moreover, government initiatives to increase awareness about diabetes and its complications along with favorable reimbursement policies are augmenting the market growth. However, high treatment costs coupled with low awareness in low-income countries is restraining market growth to some extent.

The diabetic foot ulcer treatment market consists of products and therapies used to treat foot ulcers in diabetic patients. Diabetic foot ulcers are a major complication of diabetes that can lead to infection, tissue death, and amputation if not properly treated.

Major Drivers:

  • Increasing prevalence of diabetes worldwide - According to IDF, around 537 million adults aged 20-79 years were living with diabetes in 2021. This is expected to reach 643 million by 2030.
  • Rising geriatric population - Elderly individuals are at a greater risk of developing diabetic foot ulcers due to age-related complications. The growing geriatric populace will drive market growth.
  • Increasing obesity levels - Obesity is a major risk factor for diabetes which in turn increases the risk of diabetic foot ulcers. The rising obesity rates globally will propel market growth.


  • Advent of stem cell therapy for diabetic foot ulcer treatment.
  • Use of artificial intelligence for wound assessment and monitoring.

Market Opportunity:

Huge scope for growth in developing economies due to rising diabetes prevalence and lower awareness levels about diabetic foot care.

Key Report Insights:

  • Major market driver is the growing global prevalence of diabetes. Diabetes cases have risen sharply in recent decades, increasing the number of patients at risk for diabetic foot ulcers.
  • Companies are investing in advanced wound care products, growth factors, skin grafts, and stem cell therapies to improve diabetic foot ulcer healing. New drugs are also being developed to treat infection and prevent recurrence.
  • Advances in wound imaging, pressure mapping technology, and telemedicine are improving diagnosis and monitoring of diabetic foot ulcers.
  • The market is expected to be driven by the rising adoption of regenerative medicine and stem cell therapy for wound healing.

Key Regional Insights:

  • North America was the largest region in 2023 with a 30% market share. Key players in North America include Acelity L.P. Inc., 3M Healthcare, and Organogenesis Inc. Increasing diabetes prevalence and favorable reimbursement policies are driving North America's market.
  • Europe accounted for a 28% market share in 2023. Prominent companies in Europe include Coloplast Corp, B. Braun Melsungen AG, and Smith & Nephew Plc. Rising awareness about diabetic foot ulcers is spurring market growth in Europe.
  • Asia Pacific is poised to grow at the highest CAGR during the forecast period owing to rapidly increasing diabetic population and healthcare infrastructure improvements in China and India.
  • Leading companies operating in the diabetic foot ulcer treatment market include Acelity L.P. Inc., Smith & Nephew Plc., ConvaTec Inc., Coloplast A/S, 3M Healthcare, and Molnlycke Health Care AB, URGO Medical, Medline Industries, Inc.

Market Segmentation:

  • By Product Type 
    • Wound Care Dressings
    • Biologics 
    • Therapy Devices
    • Antibiotic Medications
    • Others
  • By Ulcer Type
    • Neuropathic Ulcers 
    • Ischemic Ulcers
    • Neuro-Ischemic Ulcers
  • By End-User
    • Hospitals
    • Clinics
    • Ambulatory Surgery Centers 
    • Home Care Settings
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa


“The diabetic foot ulcer treatment market consists of products and therapies used for treating foot ulcers and wounds that occur in diabetic patients due to complications of diabetes such as peripheral arterial disease and peripheral neuropathy. Treatment options include specialized wound care dressings, skin grafts, growth factors, antibiotic medications, shockwave therapy, hyperbaric oxygen therapy, and emerging regenerative medicine approaches.

Why iDataAcumen

Actionable Insights

Access to robust insights derived from our rich internal databases and external sources

Deep Industry Acumen

Our industry experts have a keen understanding of macro and micro economic trends

Research Customization

On-demand generation of research and insights tailored to your needs

Vast Industry Coverage

We provide market intelligence services across multiple healthcare domains